The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The company plans to add 1700 beds by FY27 through the organic route
Aurigene.AI is an end-to-end solution for small molecule drug discovery
New leadership team announced at NATHEALTH Annual General Meeting 2024
Subscribe To Our Newsletter & Stay Updated